advanced ovarian cancer: making the most of mutations and biomarkers to inform treatment plans
Published Streamed 1 year ago • 54 plays • Length 1:30:27Download video MP4
Download video MP3
Similar videos
-
1:30:25
advanced ovarian cancer: making the most of mutations and biomarkers to inform treatment plans
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
54:29
3/26/2021: upfront treatment of advanced ovarian cancer; ay, now the plot thickens
-
59:02
parp inhibitors as first-line maintenance therapy in ovarian cancer
-
12:05
the rationale for hrd genomic instability testing in patients with advanced ovarian cancer
-
1:29:06
the advanced ovarian cancer treatment palette: candid conversations on parp inhibitors
-
51:46
upgrading the treatment algorithm for advanced ovarian cancer
-
34:13
expert views on the evolving role of parp inhibitors in the treatment of ovarian cancer
-
1:25
dr. borst on homologous recombination deficiency in patients with ovarian cancer
-
45:27
what is hrd (homologous recombination deficiency) and how does it impact ovarian cancer?
-
1:04:04
ovarian cancer | meet the professor: optimizing the management of ovarian cancer — part 5
-
29:07
actg dinner symposium highlights | beyond brca testing – does hrd matter? | prof michael friedlander
-
21:06
genetic testing in early and recurrent ovarian cancer | 2022 evolution conference
-
19:30
did you know? the importance of hrd testing in advanced ovarian cancer with maurie markman, md
-
8:41
impact of hrd status on frontline treatment of ovarian cancer
-
1:03:39
precision medicine in ovarian cancer with parp inhibitor therapy and companion diagnostics
-
58:12
enhancing personalized medicine in ovarian cancer: advances in parp inhibition and novel modalities
-
1:04:52
practice-changing updates in ovarian cancer: implications for pathways construction
-
29:35
front line treatment of ovarian cancer dr. thomas herzog